Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 4,226 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Cutaneous Leiomyomas, Hereditary Leiomyomatosis and Renal Cell Cancer
Interventions: Botulinum toxin type A, Placebo; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: GEO-D03 DNA vaccine, MVA/HIV62B (MVA62B) vaccine, Placebo for GEO-D03 DNA, Placebo for MVA62B:; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 1 more

Conditions: Ureter Injury
Interventions: Indigotindisulfonate sodium 0.8%, Saline injection 0.9%; Drug · Other
Lead sponsor: Prove pharm; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Albany, New York

Conditions: Acute Myocardial Infarction, Heart Failure
Interventions: Anakinra, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 110 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy
Interventions: 5 mg/N6022, Placebo, 10mg/N6022, 20mg/N6022; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Motavizumab, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 0 Months to 6 Months
Enrollment: 2,127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 12
States / cities: Chinle, Arizona • Cibecue, Arizona • Fort Definace, Arizona + 9 more

Conditions: Chronic Kidney Disease
Interventions: L-Arginine, Placebo; Drug · Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 35 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Newark, Delaware • Dallas, Texas

Conditions: Osteoarthritis of the Hand
Interventions: AMPION™, Saline; Biological
Lead sponsor: Ampio Pharmaceuticals. Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Healthy Participants
Interventions: Placebo, Pelacarsen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: Diabetic Macular Edema (DME)
Interventions: Oral BGE-102, Oral Placebo Matching BGE-102, Anti-VEGF, Sham; Drug · Other
Lead sponsor: BioAge Labs, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 16
States / cities: Bakersfield, California • Glendale, California • Mountain View, California + 13 more

Conditions: Cat Allergy, Cat Hypersensitivity
Interventions: AMG 157, Cat Immunotherapy, Cat Immunotherapy Placebo, AMG 157 Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more

Conditions: Infections, Respiratory Tract
Interventions: GSK1325756 Solution, GSK1325756 Solution Matching Placebo, GSK1325756 Tablet, GSK1325756 Tablet Matching Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hemorrhage, Surgical, Tonsillar Bleeding
Interventions: Tranexamic Acid Injectable Product, Normal Saline; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 2 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Davis, California • Providence, Rhode Island • San Antonio, Texas

Conditions: Marburg Virus Disease
Interventions: cAd3-Marburg Vaccine, Placebo; Biological
Lead sponsor: Albert B. Sabin Vaccine Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 7
States / cities: Huntsville, Alabama • Phoenix, Arizona • Melbourne, Florida + 4 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: NurOwn® (MSC-NTF cells), Placebo, Bone Marrow aspiration; Biological · Other
Lead sponsor: Brainstorm-Cell Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 3 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Brivekimig, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Columbus, Georgia • Farmington Hills, Michigan + 2 more

Conditions: Postoperative Pain, Abdominal Surgery
Interventions: SABER-Bupivacaine, Bupivacaine HCl, SABER-Placebo; Drug
Lead sponsor: Durect; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 18 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • San Antonio, Texas

Conditions: Keloid
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza, Human
Interventions: NanoFlu (Quad-NIV), Matrix-M Adjuvant, Placebo, Fluzone HD, Flublok Quadrivalent, Influenza Vaccine; Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 65 Years and older
Enrollment: 1,375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 11 more

Conditions: Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Enteropathic Arthritis, Crohn's Disease
Interventions: Herpes Zoster (HZ) Vaccine, Placebo; Biological · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 34
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 27 more

Conditions: Age Related Macular Degeneration (ARMD)
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 31
States / cities: Phoenix, Arizona • Sun City, Arizona • Huntington Beach, California + 28 more

Conditions: Hidradenitis Suppurativa
Interventions: Izokibep, Placebo to izokibep; Drug
Lead sponsor: ACELYRIN Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 20
States / cities: Birmingham, Alabama • Encino, California • Fountain Valley, California + 16 more

Search by objective public record fields.

Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency

Anakinra to Prevent Adverse Post-infarction Remodeling (2)

A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients

AP-011 Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint

A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants

A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

TEAPOT Study Multisite

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

Bupivacaine Effectiveness and Safety in SABER® Trial

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

Dupilumab in the Treatment of Keloids

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Hidradenitis Suppurativa Phase 2b Study of Izokibep